Background There is controversy regarding the use of blood eosinophil levels as a
biomarker of exacerbation risk and responsiveness of patients to inhaled corticosteroids …

There is an emerging role for blood eosinophil count (EOS) as a biomarker to guide inhaled
corticosteroid (ICS) therapy in COPD. Since ICS administration could influence EOS, we …

In patients with COPD, blood eosinophil counts can predict the effects of inhaled
corticosteroids (ICS) on exacerbation rates [1–4]. Blood eosinophil counts are now …

Reduction of the future risk of exacerbations represents one of the major aims in the
management of chronic obstructive pulmonary disease (COPD)(1). Although inhaled …

Background Growing evidence suggests that blood eosinophil count is associated with
patient responsiveness to inhaled corticosteroids (ICS). We performed post hoc predictive …

Background Chronic obstructive pulmonary disease (COPD) is characterised by progressive
airflow limitation and chronic inflammation. Predicting exacerbations of COPD, which …

Identification of a biomarker that predicts response to inhaled corticosteroids (ICS) would
help evaluate the risk/benefit profile of ICS in chronic obstructive pulmonary disease (COPD) …

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder and patients
respond differently to treatment. Blood eosinophils are a potential biomarker to stratify …

Blood eosinophils are a predictive biomarker of inhaled corticosteroid response in chronic
obstructive pulmonary disease (COPD). We investigated blood eosinophil stability over 1 …

Blood eosinophil counts have emerged as a chronic obstructive pulmonary disease (COPD)
biomarker that predict the effects of inhaled corticosteroids (ICS) in clinical practice. Post-hoc …